In a patient with ER+/HER2+ breast cancer harboring a NCOA4-RET fusion, treatment with cabozantinib in combination with trastuzumab and exemestane led to radiological tumor regression and symptomatic improvement following initial progression on the pertuzumab, trastuzumab, and anastrozole combination [72]. This evidence concerns the gene ESR1 and breast carcinoma.